No Data
No Data
Stock blogger Sanasae: Will the Nikkei Stock Average test the second bottom? Triangle consolidation? Targeting pullbacks of attention stocks [FISCO social reporter]
The following is a comment written by individual investor "Sana Sae" (blog: "Sana Sae's Beautiful Investment Life") of the FISCO Social Reporter. At FISCO, we work together with individuals who actively disseminate information to provide a wide range of information to investors. ----------- * Written on September 8, 2024 at 12 o'clock. Hello everyone, good morning/afternoon/evening. The Liberal Democratic Party's presidential election is "Is it Shunichi Koizumi or Shigeru Ishiba? Who knows..." with the right to vote.
Prism Biolab: Extraordinary Report
Volume change rate ranking (13:00) - Helios, Kan Kisen, etc. rank in.
※In the volume change rate ranking, by comparing the average volume of the past 5 days with the volume on the day of delivery, you can understand the interest of market participants such as market trends. ■Top volume change rate [September 10, 13:32 current] (comparison of average volume of the past 5 days) Code→Stock→Volume→5-day average volume→Volume change rate→Stock price change rate <6769> Zacta 1630200 236686.58 261.54% 0.2469%<9348>
Emerging markets stock digest: Daijiro made a significant rebound, while Ishin continued to decline significantly.
<7674> NATTY -130 continued decline. After the close of trading on the 6th, they announced a downward revision of their financial estimates for the cumulative period and full-year performance forecast for the second quarter of the fiscal year ending in January 2025, causing dissatisfaction. On the sales side, the new store openings of directly operated stores were delayed compared to the plan, and on the profit side, the decrease in revenue led to a decrease in gross profit. Additionally, due to the advancement of the business plan of the subsidiary "GRIP FACTORY", mainly personnel recruitment expenses and labor costs occurred ahead of schedule. Additionally,
PRISM Bio - The results of the combination trial with E7386 and lenvatinib mesylate will be presented at the European Clinical Oncology Society Annual Meeting.
The results of the combination trial of E7386, jointly developed by the company and Eisai, with lenvatinib mesylate will be announced by Eisai at the European Society for Medical Oncology Annual Congress (ESMO Congress 2024), and it is considered to be positive news. The manageable safety of the combination of E7386 and lenvatinib is demonstrated, and preliminary anti-tumor effects are also confirmed. Administration to the remaining patients is ongoing.
Individual investor, Yugetsu Yuken: The focus on australian small/mid cap stocks is reviving, drawing even more attention to biotech stocks! [FISCO Social Reporter]
The following is a comment written by individual investor "Yuugentei Tamaki" (Blog: Profitable Stock Information "The Cat's Husband's Ceilingless Stock") of the FISCO Social Reporter. At FISCO, we strive to collaborate with individuals who actively disseminate information in order to provide a wider range of information to investors. ----------- * After the news that the Ministry of Economy, Trade and Industry will compile an action plan to expand the biotechnology industry on September 2, 2024 at 13:00, biotech stocks have a wide range of
No Data
No Data